Ibnh.Am
IBNH.AM operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. IBNH.AM operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IBNH.AM operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
IBNH.AM's capital structure is characterized by a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.61, suggesting that it may face challenges in meeting short-term obligations with its current assets. The company's free cash flow is negative at -840,100, which may indicate that it is investing heavily in its operations or facing operational inefficiencies.
In terms of profitability, IBNH.AM's return on equity is 2.38%, and its return on assets is 1.06%. These figures are below the industry norms for the Healthcare Facilities & Services industry, suggesting that the company is not generating returns as efficiently as its peers. The company's operating income of 379,380 and net income of 323,470 reflect a relatively low margin, which may be a concern for investors.
The company's revenue is concentrated in the pharmaceuticals segment, with no significant geographic diversification mentioned in the available data. This concentration may expose the company to specific market risks, such as regulatory changes or shifts in demand within the pharmaceuticals sector.
The growth trajectory of IBNH.AM is not clearly defined in the available data. The company's capital expenditure of -2,206,470 indicates a significant investment in long-term assets, which may be a sign of expansion or modernization efforts. However, the lack of specific growth metrics or outlooks makes it difficult to assess the company's future performance.
The risk assessment for IBNH.AM highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which may affect its ability to fund operations without additional financing. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term.
Recent events related to IBNH.AM are not detailed in the available data. The company's financial filings and transcripts do not provide specific information on recent developments that could impact its operations or financial performance.
- IBNH.AM has a moderate debt-to-equity ratio, indicating a balanced capital structure.
- The company's return on equity and return on assets are below industry norms, suggesting inefficiencies in generating returns.
- The company's free cash flow is negative, which may indicate operational inefficiencies or significant investments.
- IBNH.AM's revenue is concentrated in the pharmaceuticals segment, which may expose it to specific market risks.
- The company's liquidity position is assessed as medium, and its dilution risk is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IBNH.AM Market data — financials · 2026-05-28